1, DILI clinical diagnosis is still exclusive diagnosis, should be combined with the history of drug use, clinical features and characteristics of dynamic changes in liver biochemical indicators, drug re-stimulation reaction, the exclusion of other causes of liver injury and other comprehensive analysis. Histological examination of liver biopsy can help in the diagnosis and differential diagnosis. (1B) Kou Jiantao, Department of Hepatobiliary, Pancreatic and Splenic Surgery, Chaoyang Hospital, Beijing, China 2. The RUCAM causality scale is recommended as a clinical diagnostic scale for DILI in clinical practice. ＞A score of >8 is Highly probable, 6-8 is Probable, 3-5 is Possible, 1-2 is Unlikely, and ≤0 is Excluded. (1B) 3. The complete clinical diagnosis of DILI should include diagnostic nomenclature, clinical type, disease duration, RUCAM score results, and severity grading. (1B) 4. DILI occurring on the basis of autoimmune hepatitis (AIH), drug-induced AIH and AIH-like DILI with autoimmune features (AL-DILI) are often difficult to differentiate. Detailed drug history and autoimmune indexes should be collected, clinical response to treatment and response after discontinuation of immunosuppressive drugs should be dynamically observed, and liver histological examination should be performed if necessary to differentiate. (2C) 5. Patients with background of underlying liver disease or multiple causes of liver injury should be monitored more closely when applying drugs with potential hepatotoxicity. The diagnosis of DILI should be made with great caution, requiring exclusion of episodes and exacerbations of pre-existing liver disease and careful screening of the most likely cause of liver injury for proper treatment. (1B) 6. The first treatment measure for DILI is to discontinue the drug suspected of causing liver injury in a timely manner, and to discontinue the drug or reduce the dose for intrinsic DILI. (1A) 7. In order to avoid the risk of aggravation of the primary disease, the discontinuation criteria in FDA drug clinical trials are available for reference (one of the following conditions): (1) serum ALT or AST > 8 ULN; (2) ALT or AST > 5 ULN for 2 weeks; (3) ALT or AST > 3 ULN and TBil > 2 ULN or INR > 1.5 (4) ALT or AST >3 ULN with progressive worsening of fatigue and gastrointestinal symptoms, etc., and/or eosinophilia (>5%). (1B) 8. For adults with early stage of drug ALF and SALF, N-acetylcysteine (NAC) is recommended as early as possible. Depending on the condition, NAC may be administered at 50-150 mg/(kg?d) for at least 3 d. (1A) In children with drug-associated ALF/SALF, NAC is not recommended for the time being.(2B) 9. Glucocorticoids should be used with great caution in the treatment of DILI, and strict indications are needed to fully weigh the benefits and possible risks of treatment. AIH-like DILI with autoimmune features (AL-DILI) mostly responds well to glucocorticoid therapy and is less likely to relapse after discontinuation of glucocorticoids. (1B) 10, magnesium isoglycyrrhizate can be used to treat acute hepatocellular or mixed DILI with markedly elevated ALT.(1A) 11, mild-moderate hepatocellular injury and mixed DILI, the more severe inflammation can be tried with dicyclomine and glycyrrhetinic acid preparations (diammonium glycyrrhizate enteric capsules or compound glycyrrhetinic acid, etc.); the less severe inflammation can be tried with silymarin; cholestatic DILI can be used Ursodeoxycholic acid (UDCA) or adenosylmethionine (SAMe) can be used for cholestatic DILI, but both are supported by high-level evidence. (2B) Combinations of more than 2 hepatoprotective anti-inflammatory drugs are not recommended, nor is prophylactic use to reduce the incidence of DILI. (2B) 12. Liver transplantation may be considered for patients with severe disease such as pharmacologic ALF/SALF and decompensated cirrhosis. (1B) 13.Hy’s rule is an important reference value for determining the prognosis of DILI. If Hy’s rule is found in the clinical trial database, the hepatotoxicity of the relevant drugs should be given high priority. (1B) 14. Different strategies and approaches should be adopted according to the different goals of DILI risk management, including identification of high-risk patients, discontinuation, dose reduction, monitoring changes in baseline and follow-up liver biochemical parameters, and weighing overall benefit and risk. (1B) 15. Clinicians should prescribe medications in strict accordance with medical needs and drug instructions, paying due attention to the principles of drug compounding and contraindications to compounding. Enhance health education and risk management for the public, be alert to the potential adverse effects of TCM-NM-HP-DS, promote change in the misconception that it is safe and non-toxic, and be alert to the hepatotoxicity of folk remedies, prescriptions and toxic plants. (1B) 16. The establishment, development, improvement and application of online interactive platforms such as HepaTox website and LiverTox website can help medical professionals and the public to know about DILI, which can be fully used in clinical practice and scientific research. (1B)